NN1177 TFA
Based on 1 Customer Validation
NN1177 (NNC9204-1177) TFA is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 TFA can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.22%
- 分子式: C206H323N51O66.xC2HF3O2
- 分子量:4570.07 (free base)
-
保管条件:
Sealed storage, away from moisture and light.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
|
CYP3A4 |
NN1177 (0.75-4 nmol/kg, s.c., once daily, 8 weeks) TFA reduces liver fat and inflammatory and fibrosis relevant biomarkers in C57Bl/6 mice fed a fructose and high fat rich diet (NASH model)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
性状 Solid
-
分子量 4570.07 (free base)
-
分子式 C206H323N51O66.xC2HF3O2
-
Color White to off-white
-
別名
NNC9204-1177 TFA
-
配列
His-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Tyr-Leu-Glu-Ser-Lys-Arg-Ala-Arg-Glu-Phe-Val-Gln-Trp-Leu-Leu-{Lys(gGlu-gGlu-Ser-Glu-Ser-gGlu-gGlu-C18 diacid)}-Thr-NH2
-
シーケンスの短縮
H-{Aib}-QGTFTSDLSKYLESKRAREFVQWLL-{Lys(γGlu-γGlu-Ser-Glu-Ser-γGlu-γGlu-C18 diacid)}-T-NH2
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Sealed storage, away from moisture and light
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
溶剤 & 溶解度
H2O : 100 mg/mL (Need ultrasonic)
DMSO : 100 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
純度とドキュメンテーション
-
データシート (288 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Simonsen L, et al. Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls. PLoS One. 2022 Mar 4;17(3):e0264974. [Content Brief]
[2]. Monfeuga T, et al. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients. Mol Metab. 2023 Dec 7;79:101850. [Content Brief]
[3]. Säll C, et al. In vitro CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic. Drug Metab Dispos. 2022 Jun 9:DMD-AR-2022-000865. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
NN1177 TFA 関連分類
HY-P10032A 関連分類
Powered by Bioz